Primary tuberculosis still occurs in our country, especially in people living in very poor conditions and in recent immigrant populations.1 This has also been shown recently by epidemiologists in the USA.1 In our department we have discovered about 100 new cases each year.
Children who are symptomatic for tuberculosis suffer mostly, among other complications, from hypertrophy of the hilar lymph nodes. These can compress bronchi and even disrupt and discharge their caseous content in the bronchial tree (fistulisation). 2' There is little information about the usefulness of corticosteroids in the treatment of bronchial obstruction in primary tuberculosis and that available in recent papers7 is often from old publications. In the 1960s there were claims for its efficacy, when given at the early onset of bronchial obstruction and before fistulisation, to prevent complications such as fistulisation and bronchiectasis.2 3 8 Other authors such as Nemir et al did not confirm this beneficial effect in a preliminary study.9 This study suffered from an uneven distribution of patients, and in a later study on a larger series of children the authors demonstrated a significant and noticeable improvement in tuberculous patients treated with steroids compared with those not treated with steroids. 10 Steroids are neither harmless nor easy to control when needed for a prolonged period of time. Hypertension and water retention as well as potassium depletion are potential risks. Furthermore it is well known that premature and abrupt interruption of steroids is often followed by a severe 'rebound' reaction.3 11 This can be even more severe than the initial lesion. Antituberculous treatment consisted of a combination of isoniazid (10 mg/kg body weight/day to a maximum 300 mg/day) and rifampicin (15 mg/kg body weight to a maximum 600 mg/day) for one year and ethambutol for two months (20 mg/kg body weight/day) providing there was no visual disturbance. Prednisolone was started at a daily dose of 2 mg/kg of body weight for 15 days and was progressively decreased to be stopped between 2-5 and 3 months. We had previously observed that within a few days of too early or abrupt an interruption of steroids patients often showed a severe rebound reaction. Sometimes there were even more extensive lesions than before the onset of prednisolone and the hazard of fistulisation had also increased.
Paediatric endocrinologists recommended that these children receiving such high doses of corticosteroids for more than one month should have a sodium restricted diet and that they should also receive potassium gluconate supplements and gastric protection by aluminium phosphate.
FOLLOW UP A few children were admitted to hospital before the start of the trial for either bronchoscopy under general anaesthesia or because of their poor general condition. All drugs were taken orally. To guarantee optimal therapeutic compliance, which was essential in the steroid group where side effects due to incorrect diet could be dangerous, and to ensure that patients were seen as scheduled, a special home care unit was set up by MT.12 GROUP 1 (STEROIDS) This group comprised 15 children (11 boys, four girls) aged 4 months to 12 years (median 6-3 years). Two were lost to follow up after six months (table 2) . GROUP 
(NO STEROIDS)
This group comprised 14 children (eight boys, six girls) aged 18 months to 15 years (median The ethical committee did not consent for double blind study because:
(1) Before the trial corticosteroids were used routinely in all patients with bronchial obstruction in primary tuberculosis and therefore patients without steroids should be known and given the possibility to interrupt the trial in case of their condition deteriorating.
(2) Patients taking corticosteroids should have sodium restricted, potassium enriched diets and patients without steroids should not. Tables 2 and 3 illustrate the characteristics and course of the children in the two groups.
Results

RADIOLOGY (TABLE 4)
Because of incomplete radiological follow up over the planned treatment period, and despite complete bronchoscopic follow up during the first months of the study, information on 1, 5, 11, 12) who were randomised in group 2, worsened on both evidence from the radiographs and bronchoscopy despite one month of correct antituberculous treatment and eventually corticosteroids were added to their treatment. They then improved but to avoid any bias they were not included for statistical evaluation in group 1. In group 1 one patient (case 12), known for his poor therapeutic compliance, developed a bronchial fistula after three months. Another patient from the same group (case 7), who developed successively measles and respiratory syncytial virus infections at the fourth month after the start of the treatment, then showed bronchial fistulisation, despite perfect therapeutic compliance. In fact these two children showed fistulisation after the end of the steroid treatment and not during it. The number of children who needed more than two bronchoscopies was appreciably higher in the group not taking steroids than in the steroid group (six patients compared with one).
Discussion
In our department most of the children with primary tuberculosis come from a high risk group. They are mostly immigrant families, originating from underdeveloped countries, though the infection often takes place in our country because of bad housing and working conditions. This accounts for the very high rate of 18 positive cultures for M tuberculosis on these 29 patients and is also representative of the severity of the clinical symptoms and radiological abnormalities at the onset of the diagnosis.
The relatively small number of drop outs, despite the fact that many families could not express themselves in one of the local languages, can be attributed to the home care structure stimulating trust and enabling a close and correct drug monitoring.12
There is a relatively clear agreement on how to use the different specific antituberculous drugs in monotherapy or in combination, depending on the clinical picture.4 5 7 13 The aim of our study was not to re-evaluate this and anyway all our patients were cured of their infection, whether steroids were added or not. Our goal was limited to the examination of the effect of prednisolone on bronchial compression by lymph nodes before the disruption occurred. Nemir et al also showed an effect on the course after fistulisation,10 but we preferred not to include the latter in order to have a homogeneous series needing fewer patients.
The beneficial effect of corticosteroids in combination with antituberculous drugs is well known in important pleural effusion.'
Adding corticosteroids in the first three months of antituberculous treatment has also been studied in adults with advanced cavitary pulmonary tuberculosis, and showed a favourable influence on radiological and clinical course and on pulmonary function.1 Despite older and less active tuberculostatics these patients did not run a greater risk.
As stressed in the introduction, little information is available about the usefulness of corticosteroids in childhood primary tuberculosis, and we were not able to find any recent study. Nemir Our study showed a more even distribution of the patients in two comparable samples to that of the patients reported by Nemir et al in their preliminary study. There were no significant bacteriological, radiological, or bronchoscopic differences between our two groups before the onset of any treatment (tables 2 and 3). The only difference was that the steroid group was slightly younger and therefore may be at a higher possible risk for complications. Otherwise the severity of the disease was similar in both groups and the beneficial effect of the steroid treatment as reflected by the different course or outcome is certainly neither coincidental, nor due to any bias.
This modest study, performed on a small number of patients, still clearly demonstrates the benefit of adding prednisolone whenever bronchial compression is demonstrated, and before airways are damaged by caseous fistulas, even though all patients were given a combination of very active antituberculous drugs including rifampicin, not used in the previous studies.
Though in both groups the bronchial lesions improved significantly under treatment, it was faster and more noticeable in the steroid group. Moreover, the risk of complications known to occur on steroid treatment appeared only during uncontrollable or unexpected events, such as severe viral superinfection or poor therapeutic compliance. On the contrary, in the group not taking steroids, fistulisation occurred more often and on a few occasions previously mild compressions worsened and these improved only after the addition of prednisolone. Cushing's syndrome has never been seen in our patients, thanks to a thorough salt restricted diet and other precautions.
We conclude that whenever severe bronchial compression has been demonstrated, steroids remain beneficial and should be added to the specific antituberculous treatment notwithstanding the available powerful antituberculous drugs and despite the fact that this will increase the load of the treatment. The benefit was sufficiently noticeable and significant even in this small series to consider it unethical to continue the trial. All eligible patients should benefit from steroid treatment under optimal conditions.
The patient's or family's compliance should be carefully evaluated before starting steroids, as the risk of damage as a consequence of poor administration or an incorrect diet would be greater than the expected benefit. Patients with bronchial compression not receiving steroids should be carefully and closely observed, as they will perhaps need more therapeutic bronchoscopies.
